At the news
? BULLISHIMPACT 6/10 8-K filed Nov 9, 2026 at 08:45 ET
Faeth Therapeutics reported topline Phase 2 data for PIKTOR (serabelisib + sapanisertib) plus paclitaxel in advanced endometrial cancer, showing a 33% confirmed ORR and preliminary median PFS of 7.4 months in a heavily pre-treated population. The safety profile appears differentiated with low rates of hyperglycemia and stomatitis. The company plans to disclose a registrational trial design by 1H 2027.
- Confirmed ORR of 33% (12/36) in efficacy-evaluable patients; DCR of 83%
- Preliminary median PFS of 7.4 months (95% CI 5.3, NR) in all 42 treated patients
- Preliminary 6-month PFS rate of 62% (95% CI 43, 75)
- Confirmed ORR of 44% and DCR of 81% among patients with PIK3CA mutation
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access